# Zylox-Tonbridge and GL Capital invest HK$1.482B in LifeTech Scientific

Zylox-Tonbridge and GL Capital will jointly invest approximately HK$1.482 billion in LifeTech Scientific for a 16.7% stake. Zylox-Tonbridge will invest HK$889 million and intends to pursue a potential merger with LifeTech.

- Type: Investment
- Announced: 2026-11-06
- Where: China
- Value: $190.0M (1.48B HKD)
- Status: announced
- Products: peripheral vascular devices, neurovascular devices, aortic devices, structural heart devices
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [LifeTech Scientific](https://endata.com/companies/38475.md) (target)
- [Zylox-Tonbridge Medical Technology](https://endata.com/companies/94974.md) (investor)
- [GL Capital](https://endata.com/companies/94975.md) (investor)

## Sources

- [prnewswire.com](https://www.prnewswire.com/news-releases/zylox-tonbridge-and-gl-capital-announce-strategic-investment-in-lifetech-scientific-to-build-a-leading-vascular-and-structural-heart-intervention-platform-302932244.html), 2026-11-06: "The investment is expected to bring together Zylox-Tonbridge's peripheral vascular and neurovascular businesses with LifeTech's aortic and structural heart businesses, creating a comprehensive portfolio across four key therapeutic areas."
- [prnewswire.com](https://www.prnewswire.com/news-releases/zylox-tonbridge-and-gl-capital-announce-strategic-investment-in-lifetech-scientific-to-build-a-leading-vascular-and-structural-heart-intervention-platform-302932258.html), 2026-11-06: "The investment is expected to bring together Zylox-Tonbridge's peripheral vascular and neurovascular businesses with LifeTech's aortic and structural heart businesses, creating a comprehensive portfolio across four key therapeutic areas."
- [prnewswire.co.uk](https://www.prnewswire.co.uk/news-releases/zylox-tonbridge-and-gl-capital-announce-strategic-investment-in-lifetech-scientific-to-build-a-leading-vascular-and-structural-heart-intervention-platform-302932258.html), 2026-11-06: "The investment is expected to bring together Zylox-Tonbridge's peripheral vascular and neurovascular businesses with LifeTech's aortic and structural heart businesses, creating a comprehensive portfolio across four key therapeutic areas."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.